Neil Osheroff
-
Osheroff Lab contributed data leading to FDA approval of treatment for gonorrhea
Crucial research by Neil Osheroff and his lab led to FDA approval of the first new class of antibacterial drugs in decades. The drug, gepotidacin, developed by GlaxoSmithKline under the brand name Blujepa, is now approved to treat uncomplicated urinary tract infections and gonorrhea. Read MoreApril 28, 2025
-
Vanderbilt biochemists contribute to breakthrough discovery of first new antibacterial class in decades
Led by Neil Osheroff, Vanderbilt researchers are the first to undertake a systematic analysis of the mechanism of action of gepotidacin, a first-in-class triazaacenaphthylene antibacterial, against its targets in Escherichia coli—the type II topoisomerases gyrase and topoisomerase IV—and the mechanistic basis for drug resistance. E. coli is the etiological agent of most urinary tract infections. Read MoreMarch 28, 2024
-
Osheroff receives Distinguished Teacher Award from Association of American Medical Colleges
As a professor of biochemistry and medicine at Vanderbilt University School of Medicine for more than 40 years, Osheroff is the longest serving course director currently teaching medical students. He also codirects the preclerkship phase of the medical school curriculum and leads the Master Science Teachers cohort, a role established in 2007 to recognize VUSM’s outstanding basic science educators. Through his teaching, he has helped medical students at VUSM and across the globe acquire the basic science skills and knowledge they need to thrive in clinical practice, according to the AAMC. Read MoreOctober 31, 2023
-
Crowe, Osheroff honored by AAMC
Vanderbilt's James E. Crowe, Jr, MD, and Neil Osheroff, PhD, are among 12 individuals honored by the Association of American Medical Colleges during its 2023 Awards Recognition Event. Read MoreOctober 30, 2023
-
Osheroff wins prestigious MILES Award
Neil Osheroff received the Mentoring, Innovation, and Leadership in Educational Scholarship Award at the annual Asia Pacific Medical Education Conference that took place in May. Read MoreJuly 7, 2023
-
Correctly copying DNA
New research into the enzyme topoisomerase II sheds light on how it helps DNA replicate properly. Read MoreMarch 14, 2019
-
Confronting TB resistance
Vanderbilt researchers describe how certain tuberculosis treatments work and suggest these medications may overcome the threat of drug-resistant tuberculosis. Read MoreJune 11, 2018
-
Novel insights to antibiotic targets
New mechanistic details about the DNA-unwinding activity of antibacterial protein targets could lead to the design of better antibiotic medicines. Read MoreSeptember 29, 2017
-
Slight chemical change may improve TB treatments: study
One small chemical change to an existing antibacterial drug results in a compound that is more effective against its target enzyme in tuberculosis, Vanderbilt researchers have discovered. Read MoreFebruary 11, 2016
-
Anticancer olive compounds
Compounds found in olives and olive oil have anticancer activity, which may contribute to the cancer preventive properties attributed to the Mediterranean diet. Read MoreJuly 27, 2015